N-[(2-methoxyethyl)amidino]thiourea

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫脲类
• 英文名称: N-[(2-methoxyethyl)amidino]thiourea
• 英文别名: N-(2-methoxyethyl)amidinothiourea；(2-methoxyethyl)amidinothiourea；[N'-(2-methoxyethyl)carbamimidoyl]thiourea
• 化学式: C₅H₁₂N₄OS
• 分子量: 176.242
• InChiKey: YDVQOPMXPKPQIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[(2-methoxyethyl)amidino]thiourea 、 3-phthalimidophenacylbromide 以 乙腈 为溶剂， 生成 2-[2-(2-methoxyethyl)guanidino]-4-(3-phthalimidophenyl)thiazole hydrobromide
  参考文献：
  名称：

  Antisecretory guanidine derivatives and pharmaceutical compositions

  摘要：

  醇胺衍生物的化学式为：##STR1## 其中X为氧或硫；Y为N、CH或CCH.sub.3；m为0或1；R.sup.1为氢，R.sup.2为氰基、三氟乙酰基、C.sub.1-6烷酰基、4,5-二氢-4-氧代噻唑-2-基或A-B，其中A为3,4-二氧代环丁烷-1,2-二基或C.dbd.Z，Z为氧、硫、NCN、NNO.sub.2、CHNO.sub.2、NCONH.sub.2、C(CN).sub.2、NCOR.sup.6、NCO.sub.2R.sup.6、NSO.sub.2R.sup.6或NR.sup.7，其中R.sup.6为C.sub.1-6烷基，R.sup.7为氢或C.sub.1-6烷基，B为C.sub.1-6烷基、烷氧基或烷基硫基或NR.sup.8R.sup.9，其中R.sup.8和R.sup.9为氢、C.sub.1-10烷基、C.sub.3-10-烯基、炔基或烷氧基烷基、C.sub.2-6（一次羟基）烷基，或者当R.sup.9为氢时，R.sup.8为2-[[5-二甲基氨基甲基呋喃-2-基]甲硫基]-乙基氨基，或R.sup.8和R.sup.9一起为含有额外N或O的5-或6-元非芳香环，或者R.sup.1和R.sup.2一起为咪唑啉-2-基；R.sup.3为氢或氟；R.sup.4为卤素或甲基；R.sup.5为氢、C.sub.1-6烷基或C.sub.3-10烷氧基烷基；以及它们的盐。

  公开号：

  US04315009A1

文献信息

• Substituted guanidine derivatives, processes, pharmaceutical
  申请人：ICI Americas Inc.

  公开号：US04464374A1

  公开（公告）日：1984-08-07

  The invention relates to a guanidine derivative of the formula: ##STR1## in which W is a 2-6C alkylene chain optionally substituted by 1 or 2 1-4C alkyls; E is O, S, SO, SO.sub.2 or NR.sup.3 in which R.sup.3 is H or 1-6C alkyl; R.sup.1 is H or a straight chain 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls; or R.sup.1 and R.sup.3 are joined to form a morpholine, pyrrolidine, piperidine or piperazine ring; X, P, Y, Q and R.sup.2 are as defined in the specification, and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing process, pharmaceutical compositions and intermediates are also described. The compounds of the formula I are histamine H-2 antagonists.

  本发明涉及公式为：##STR1##的胍基衍生物，其中W是2-6C的烷基链，可选地被1或2个1-4C的烷基取代；E是O，S，SO，SO.sub.2或NR.sup.3，其中R.sup.3是H或1-6C的烷基；R.sup.1是H或一条直链1-6C的烷基，可选地被1或2个1-4C的烷基取代；或者R.sup.1和R.sup.3结合形成吗啡啶，吡咯烷，哌啶或哌嗪环；X，P，Y，Q和R.sup.2如规范中定义的，并且其药物可接受的酸加成盐。还描述了制造过程，制药组合物和中间体。公式I的化合物是组胺H-2拮抗剂。
• H.sub.2 -receptor antagonist thiazoles
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05532258A1

  公开（公告）日：1996-07-02

  Thiazole compounds of formula ##STR1## are provided which have antiulcer activity and H.sub.2 -receptor antagonism, wherein R.sup.2 is lower alkyl or lower alkoxy(lower)alkyl, R.sup.3 is hydrogen, A is methylene and R.sup.1 is lower alkyl.

  提供具有抗溃疡活性和H.sub.2-受体拮抗作用的式为##STR1##的噻唑化合物，其中R.sup.2是低级烷基或低级烷氧基（低级）烷基，R.sup.3是氢，A是亚甲基，R.sup.1是低级烷基。
• Antisecretory guanidine derivatives and pharmaceutical compositions
  申请人：Imperial Chemical Industries Limited

  公开号：US04315009A1

  公开（公告）日：1982-02-09

  The guanidine derivative has the formula: ##STR1## where X is O or S: Y is N, CH or CCH.sub.3 : m is 0 or 1: R.sup.1 is hydrogen and R.sup.2 cyano, trifluoroacetyl, C.sub.1-6 alkanoyl, 4,5-dihydro-4-oxothiazol-2-yl or A-B where A is 3,4-dioxocyclobutene-1,2-diyl or C.dbd.Z where Z is oxygen, sulphur, NCN, NNO.sub.2, CHNO.sub.2, NCONH.sub.2, C(CN).sub.2, NCOR.sup.6, NCO.sub.2 R.sup.6, NSO.sub.2 R.sup.6 or NR.sup.7 where R.sup.6 is C.sub.1-6 alkyl and R.sup.7 is hydrogen or C.sub.1-6 alkyl and B is C.sub.1-6 alkyl, alkoxy or alkylthio or NR.sup.8 R.sup.9 where R.sup.8 and R.sup.9 are hydrogen, C.sub.1-10 alkyl, C.sub.3-10 -alkenyl, alkynyl or alkoxyalkyl, C.sub.2-6 (primary hydroxy)alkyl, or, when R.sup.9 is hydrogen, R.sup.8 is 2-[[5-dimethylaminomethylfuran-2-yl]methylthio]-ethylamino or R.sup.8 and R.sup.9 are together a 5- or 6-membered non-aromatic ring optionally containing an additional N or O; or R.sup.1 and R.sup.2 are together imidazolidin-2-ylidene: R.sup.3 is hydrogen or fluorine: R.sup.4 is halogen or methyl: R.sup.5 is hydrogen, C.sub.1-6 alkyl or C.sub.3-10 alkoxyalkyl: and the salts thereof.

  醇胺衍生物的化学式为：##STR1## 其中X为氧或硫；Y为N、CH或CCH.sub.3；m为0或1；R.sup.1为氢，R.sup.2为氰基、三氟乙酰基、C.sub.1-6烷酰基、4,5-二氢-4-氧代噻唑-2-基或A-B，其中A为3,4-二氧代环丁烷-1,2-二基或C.dbd.Z，Z为氧、硫、NCN、NNO.sub.2、CHNO.sub.2、NCONH.sub.2、C(CN).sub.2、NCOR.sup.6、NCO.sub.2R.sup.6、NSO.sub.2R.sup.6或NR.sup.7，其中R.sup.6为C.sub.1-6烷基，R.sup.7为氢或C.sub.1-6烷基，B为C.sub.1-6烷基、烷氧基或烷基硫基或NR.sup.8R.sup.9，其中R.sup.8和R.sup.9为氢、C.sub.1-10烷基、C.sub.3-10-烯基、炔基或烷氧基烷基、C.sub.2-6（一次羟基）烷基，或者当R.sup.9为氢时，R.sup.8为2-[[5-二甲基氨基甲基呋喃-2-基]甲硫基]-乙基氨基，或R.sup.8和R.sup.9一起为含有额外N或O的5-或6-元非芳香环，或者R.sup.1和R.sup.2一起为咪唑啉-2-基；R.sup.3为氢或氟；R.sup.4为卤素或甲基；R.sup.5为氢、C.sub.1-6烷基或C.sub.3-10烷氧基烷基；以及它们的盐。